



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Himmelsbach, F. et al ) Art Unit: 1614  
Serial No. : 09/934,753 ✓ ) Examiner:  
Confirmation No. : 8721  
Filed : 08/22/2001 ✓  
For : Aminoquinazolines Which Inhibit Signal Transduction Mediated By  
Tyrosine Kinases ✓  
Docket No. : 5/1301

TECH CENTER 160012900

MAR 06 2002

RECEIVED

Commissioner for Patents  
Washington, D.C. 20231

February 12, 2002

**TRANSMITTAL LETTER FOR  
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:


Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §§1.56 and

☒ 1.97(b). This Statement is being filed within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or before the mailing of a first Office Action on the merits, whichever event occurs last.

☒ The Assistant Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

  
Alan R. Stempel  
Attorney for Applicant(s)  
Reg. No. 28,991

Patent Department  
Boehringer Ingelheim Corp.  
900 Ridgebury Road, P.O. Box 368  
Ridgefield, CT. 06877  
Tel.: (203) 798-4868

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, DC 20231

on February 12, 2002

  
By: Alan R. Stempel, Reg. No. 28,991